Dropdown

EE - Estonia
All companies
    All persons

      Search word:

      Field/EMTAK

      MEDPHARMA OÜ

      Media page and news feed
      ?
      ?
      profile visits
      1,670
      ?
      company tracker
      2
      This company's branding has already reached 1,670 peopleand his is followed by 2 Storybook users.On average, the company has been rated 2.5 points.but there is

      MEDPHARMA OÜ current status

      2184939_andmerobot_99391772_a_xl.jpg
      Andmerobot
      Did you notice typos in the article?

      Dropdown

      This company's branding has already reached 1,670 peopleand his is followed by 2 Storybook users.On average, the company has been rated 2.5 points.but there is no comment.

      Tegevusaruanne 2024

      OÜ Medpharma esmaregistreeriti 01.12.2011.

      Ettevõtte põhitegevusalaks on ravimite ja muude apteegikaupade hulgimüük (EMTAK kood 46461).

      2023.aastast käivitus vahepeal pausil olnud müügitegevus. Sarnane tegevus jätkus ka 2024. aastal ning majandusaasta lõppes kasumlikult.

      Juhtkonnale tasu ei makstud.

      Comments (0)

      Are you sure you want to delete this article?

      Dropdown

      all articles

      File a complaint

      Choose the comment attribute that you think it contains:

      False information
      Spam
      Hate speech
      Terrorism
      Other

      You want to report an inappropriate comment.

      Are you sure?

      Are you sure you want to delete this article?

      Loader

      Loader

      App Ad

      Scorestorybook Chrome extension

      The Storybook extension tells you which company's website you are currently on and how reliable that company is today. download extension

      See the background of the caller! Storybook App brings you direct contacts for 400,000 Estonian companies and individuals (managers, officials). The data is enriched with solvency and financial information.

      We value your privacy

      We use cookies to improve your browsing experience, provide personalized ads or content, and analyze our traffic. By clicking "allow all", you agree to our use of all cookies.